Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies

25/08/2015 - 2 minutes

Two German biotechs with highly successful platforms join forces to fight cancer. MorphoSys and Immatics Biotechnologies want to generate novel antibody-based therapeutics against multiple cancer antigens.

They are two of the thriving forces in the German biotech scene. Munich’s MorphoSys claims having developed the most successful antibody library technology in the pharma industry, currently has 100 distinct drugs in research and development and is worth €1.67Bn. Tübingen-based Immatics owns the leading target discovery platform in cancer immunotherapy and raised over €120M. And now they want to team up. What a match!

Here’s how they want to tackle cancer: Tumor cells contain specific peptides that are not present in healthy cells. These are presented on the surface through specialized receptors, so-called major histocompatibility complex (MHC) receptors. The collaboration between Immatics and MorphoSys aims to discover antibodies against these MHC-bound peptide targets in order to kill the tumor cells.

Within the collaboration, MorphoSys gets several tumor-associated peptides that were discovered using Immatics’ platform. These are present in a number of solid and hematological cancers and can be used as antibody targets.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!